Wegovy HD and CagriSema, the next bar for injectable GLP-1s

Key takeaways

• Wegovy HD is semaglutide 7.2 mg once weekly. The FDA approved it on March 19, 2026 under the Commissioner's National Priority Voucher pathway for adults with obesity, or with overweight plus a weight-related comorbidity .
• STEP UP (Wharton 2025, Lancet Diabetes Endocrinology, n=1,407, 72 weeks) reported a mean body weight reduction of about 20.7 percent at 7.2 mg on the trial-product estimand (participants who took the drug as randomized), compared with about 17.5 percent at the existing 2.4 mg dose and 2.4 percent on placebo. Roughly 33.2 percent of the 7.2 mg group reached at least 25 percent body weight loss .
• REDEFINE-1 (Garvey 2025, New England Journal of Medicine, n=3,417, 68 weeks) reported a mean body weight reduction of 20.4 percent on cagrilintide-semaglutide versus 3.0 percent on placebo on the treatment-policy estimand (22.7 percent on the trial-product estimand, which assumes full adherence), in adults with overweight or obesity without diabetes .
• REDEFINE-2 (Davies 2025, New England Journal of Medicine, n=1,206, 68 weeks) reported a mean body weight reduction of 13.7 percent on cagrilintide-semaglutide versus 3.4 percent on placebo in adults with overweight or obesity and type 2 diabetes .
• CagriSema is investigational. Novo Nordisk filed a US new drug application in December 2025 ; no FDA-approved label or dose exists yet. Compounded preparations are not the trial drug and have separate FDA-flagged dosing-error concerns .

Skip to:

• What actually changed at higher semaglutide exposure
• STEP UP, what the 7.2 mg trial actually showed
• REDEFINE, what CagriSema actually showed
• Why adding cagrilintide matters
• Tolerability and adherence at higher exposure
• The lean-mass question that higher doses do not resolve
• Regulatory status and compounding posture
• Editorial summary

What actually changed at higher semaglutide exposure

Wegovy HD is the FDA-approved 7.2 mg semaglutide formulation; CagriSema is the investigational cagrilintide plus semaglutide combination. Both raise the injectable GLP-1 bar above the 2.4 mg semaglutide dose that anchored the 2021 Wegovy approval. The starting point for either jump is what STEP-1 measured.

Wegovy launched at 2.4 mg once weekly because that was the dose tested in STEP-1, the pivotal Phase 3 trial that anchored the 2021 FDA approval. In STEP-1 (Wilding 2021 NEJM, n=1,961, 68 weeks), adults with overweight or obesity and no diabetes lost on average 14.9 percent of their body weight, compared with 2.4 percent on placebo .

After STEP-1, the open mechanism question was whether 2.4 mg was the ceiling for semaglutide or whether the dose response was still climbing. GLP-1 receptor agonism is exposure-dependent for both efficacy (gastric emptying, satiety signaling, insulin secretion) and tolerability (nausea, vomiting, diarrhea). Pushing exposure higher was expected to move both curves at once. The practical bet was that the efficacy curve had more headroom than the tolerability curve had remaining slope.

STEP UP was designed to answer that question directly. It used the same 16-week dose escalation schedule that ends at 2.4 mg in the existing Wegovy label (mapped out in the semaglutide dose calculator), then continued upward to a maintenance dose of 7.2 mg .

STEP UP, what the 7.2 mg trial actually showed

STEP UP (ClinicalTrials.gov NCT05646706) was a Phase 3b, randomized, double-blind, placebo-controlled and active-controlled trial across 95 sites in 11 countries. It enrolled 1,407 adults with a body mass index of 30 or higher and without diabetes, randomized 5:1:1 to once-weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, with a lifestyle intervention, for 72 weeks .

There are two weight numbers to read. On the treatment-policy estimand (every randomized participant, including those who discontinue), the mean body weight reduction at 72 weeks was about 18.7 percent at 7.2 mg, 15.6 percent at 2.4 mg, and 3.9 percent on placebo. On the trial-product estimand (participants who took the trial drug as randomized), the reduction was about 20.7 percent at 7.2 mg, 17.5 percent at 2.4 mg, and 2.4 percent on placebo. The 20.7 percent trial-product figure is the headline number most often quoted in coverage of the FDA approval .

The responder analysis is where 7.2 mg pulls clearly away from 2.4 mg. About 33.2 percent of the 7.2 mg adherent cohort reached at least 25 percent body weight loss at 72 weeks, versus about 16.7 percent on 2.4 mg and 0 percent on placebo. The odds-ratio analyses reported a 2.4-fold higher likelihood of reaching that threshold at 7.2 mg compared with 2.4 mg .

Adverse events in STEP UP looked dose-related and class-typical for GLP-1 receptor agonists: nausea, diarrhea, vomiting, constipation, and decreased appetite, mostly mild to moderate, concentrated during dose escalation. Serious adverse events were reported in about 6.8 percent of the 7.2 mg arm and 10.9 percent of the 2.4 mg arm and 5.5 percent of placebo, so the higher dose did not produce a higher serious-event rate than the existing approved dose in this trial .

REDEFINE, what CagriSema actually showed

CagriSema is the fixed-ratio combination of two molecules: cagrilintide, a once-weekly long-acting amylin analog, and semaglutide, the GLP-1 receptor agonist behind Wegovy and Ozempic. Both arms of the Phase 3 REDEFINE program titrated the two components in parallel to 2.4 mg each per week .

REDEFINE-1 (Garvey 2025 NEJM, NCT05567796) randomized 3,417 adults with overweight or obesity and no diabetes 21:3:3:7 across cagrilintide-semaglutide (n=2,108), semaglutide alone (n=302), cagrilintide alone (n=302), and placebo (n=705), with a 68-week treatment period and a lifestyle intervention. The primary endpoint was percent change in body weight. On the treatment-policy estimand, the NEJM primary analysis, the combination arm reported a mean body weight reduction of about 20.4 percent, compared with about 14.9 percent on semaglutide alone, 11.5 percent on cagrilintide alone, and 3.0 percent on placebo . On the trial-product estimand, the effect if everyone stays on treatment, the combination reached 22.7 percent; that is the number Novo Nordisk leads with in its own summary (manufacturer-issued, treated here as a company source) .

REDEFINE-2 (Davies 2025 NEJM) randomized 1,206 adults with overweight or obesity and type 2 diabetes to cagrilintide-semaglutide or placebo for 68 weeks, again at 2.4 mg of each component. The combination produced a mean body weight reduction of about 13.7 percent compared with 3.4 percent on placebo. The smaller magnitude relative to REDEFINE-1 is consistent with the historical pattern across this drug class, where weight loss tends to be lower in adults with type 2 diabetes than in adults without it on the same drug .

Why adding cagrilintide matters

Amylin is a pancreatic hormone co-secreted with insulin from beta cells. At the receptor level it slows gastric emptying, suppresses postprandial glucagon, and acts on central appetite circuits in the area postrema and hypothalamus. Cagrilintide is a structurally modified amylin analog with a half-life suitable for once-weekly dosing, paired in CagriSema with semaglutide so that both the GLP-1 axis and the amylin axis are engaged at the same time .

The original Phase 2 monotherapy trial for cagrilintide (Lau 2021, Lancet, n=706 randomized, 26 weeks: about 506 across five cagrilintide strengths of 100 to 102 each, 99 on liraglutide 3.0 mg as an active comparator, and 101 on placebo) reported mean body weight reductions of about 6.0 to 10.8 percent across the 0.3 to 4.5 mg dose range, compared with 3.0 percent on placebo. Cagrilintide alone is therefore not in the semaglutide class on magnitude, but the question for the combination is whether the two mechanisms stack .

REDEFINE-1 read the cagrilintide-alone arm at 11.5 percent and the semaglutide-alone arm at 14.9 percent, with the combination at 20.4 percent. The combination did not equal the sum of the parts, but it added a clear increment to semaglutide alone at the same 2.4 mg dose used in Wegovy. That increment is the strongest current case for adding amylin co-agonism on top of GLP-1 .

Tolerability and adherence at higher exposure

The simplest read on Wegovy HD tolerability is that the 7.2 mg arm in STEP UP did not look meaningfully worse than the existing 2.4 mg arm on serious events. Class-typical gastrointestinal adverse events still occurred and were dose-related; the discontinuation pattern reported in the trial publication was consistent with the existing dose escalation experience .

The harder question, which the trial does not answer, is how a 7.2 mg maintenance dose performs in real-world adherence outside a Phase 3b cohort. Trial participants are selected, supported through escalation, and incentivized to stay on drug; the gap between the treatment-policy and trial-product estimands in STEP UP (about 2 percentage points at 7.2 mg) is one signal of how adherence pulls the average down even inside a controlled study. Real-world drop-off from higher doses is plausibly larger.

CagriSema tolerability sits in a slightly different place. REDEFINE-1 reported gastrointestinal adverse events at rates consistent with high-dose GLP-1 receptor agonism, with the addition of amylin-related effects that were generally mild. Whether amylin co-agonism reduces or amplifies the tolerability burden of GLP-1 alone at the same exposure is a question the head-to-head REDEFINE arms partially address, but a dedicated tolerability comparison is not yet published .

The lean-mass question that higher doses do not resolve

Larger total weight loss brings a familiar follow-on: how much of the loss is fat and how much is lean mass. The pepSmart write-up on GLP-1 and muscle loss covers what the existing DEXA substudies in STEP and SURMOUNT actually measured. In short, lean-mass loss tracks roughly proportionally to weight loss when there is no resistance training, and the absolute lean-mass loss scales with the absolute total loss.

Body composition substudies from STEP UP at 7.2 mg and from the REDEFINE program have not all been published in peer-reviewed form at the time of writing. Until those substudies report, what holds is that 7.2 mg semaglutide and CagriSema both deliver more total weight reduction than 2.4 mg semaglutide, and the lean-mass implications scale with that total. None of the trial data so far argue that the higher-exposure formulations are more lean-mass-sparing than the existing 2.4 mg formulation; the burden of proof for that claim sits with the eventual substudy data .

Regulatory status and compounding posture

Wegovy HD (semaglutide 7.2 mg) is FDA-approved as of March 19, 2026. The approval was the fourth issuance under the Commissioner's National Priority Voucher pilot, with a reported review time of about 54 days from filing. The approved indication mirrors the existing Wegovy 2.4 mg indication: chronic weight management in adults with obesity, or with overweight plus a weight-related comorbidity, alongside diet and physical activity .

CagriSema is not FDA-approved. Novo Nordisk submitted a US new drug application in December 2025 on the basis of the REDEFINE-1 and REDEFINE-2 results, with an FDA decision expected in 2026 . There is no approved label, dose, or indication yet. CagriSema is not on the FDA bulk substances list for traditional pharmacy compounding under section 503A; preparations labeled as cagrilintide or as a cagrilintide-semaglutide combination from compounding pharmacies or online vendors are not the trial drug, and the identity, purity, and dosing accuracy of those preparations cannot be assumed from the published trial data .

Editorial summary

The injectable GLP-1 bar moved twice in the last year. Higher-dose Wegovy moved it by raising the maintenance exposure of an already-approved molecule, adding about 3 percentage points of mean weight loss over the 2.4 mg dose at 72 weeks (20.7 versus 17.5 percent on the trial-product estimand). CagriSema moved it by adding a second receptor axis at the same 2.4 mg dose, adding about 5 percentage points over semaglutide alone in REDEFINE-1 (20.4 versus 14.9 percent on the treatment-policy estimand). Both sit below what retatrutide's triple-agonist Phase 3 readouts are reporting, the bar this class is now chasing (see how much weight loss retatrutide delivers).

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 12 entries, primary canon (FDA, ClinicalTrials.gov, PubMed) plus two Novo Nordisk manufacturer summaries acknowledged inline, last reviewed 2026-07-08.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.